Albemarle Co. (NYSE:ALB) has been assigned a consensus recommendation of “Buy” from the eleven research firms that are covering the stock. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $119.88.

Several analysts have recently issued reports on ALB shares. Robert W. Baird boosted their price objective on shares of Albemarle to $125.00 in a research note on Wednesday, March 1st. Zacks Investment Research raised shares of Albemarle from a “hold” rating to a “buy” rating and set a $119.00 price objective for the company in a research note on Tuesday, March 21st. Jefferies Group LLC reissued a “buy” rating and set a $120.00 price objective (up from $105.00) on shares of Albemarle in a research note on Wednesday, March 1st. Aegis started coverage on shares of Albemarle in a research note on Friday, February 17th. They set a “buy” rating and a $108.00 price objective for the company. Finally, Instinet boosted their price objective on shares of Albemarle from $102.00 to $118.00 and gave the company a “buy” rating in a research note on Wednesday, March 1st.

Albemarle (NYSE:ALB) traded up 0.55% on Friday, reaching $110.60. The company’s stock had a trading volume of 356,216 shares. The stock has a market capitalization of $12.25 billion, a P/E ratio of 26.88 and a beta of 1.41. Albemarle has a 52 week low of $74.35 and a 52 week high of $112.88. The firm has a 50 day moving average price of $107.53 and a 200 day moving average price of $96.17.

Albemarle (NYSE:ALB) last announced its quarterly earnings data on Wednesday, May 3rd. The specialty chemicals company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.10. Albemarle had a net margin of 6.92% and a return on equity of 14.38%. The company had revenue of $722.06 million during the quarter, compared to analysts’ expectations of $678.74 million. On average, equities analysts anticipate that Albemarle will post $4.36 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 3rd. Investors of record on Thursday, June 15th will be issued a dividend of $0.32 per share. The ex-dividend date is Tuesday, June 13th. This represents a $1.28 annualized dividend and a dividend yield of 1.16%. Albemarle’s payout ratio is 63.54%.

Several institutional investors have recently bought and sold shares of ALB. Sumitomo Mitsui Trust Holdings Inc. raised its position in Albemarle by 5.8% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 345,337 shares of the specialty chemicals company’s stock valued at $29,523,000 after buying an additional 18,832 shares during the last quarter. World Asset Management Inc raised its position in Albemarle by 1.4% in the third quarter. World Asset Management Inc now owns 11,511 shares of the specialty chemicals company’s stock valued at $984,000 after buying an additional 159 shares during the last quarter. Sumitomo Mitsui Asset Management Company LTD raised its position in Albemarle by 10.7% in the third quarter. Sumitomo Mitsui Asset Management Company LTD now owns 8,626 shares of the specialty chemicals company’s stock valued at $737,000 after buying an additional 832 shares during the last quarter. Huntington National Bank raised its position in Albemarle by 132.0% in the third quarter. Huntington National Bank now owns 11,578 shares of the specialty chemicals company’s stock valued at $990,000 after buying an additional 6,588 shares during the last quarter. Finally, Jennison Associates LLC raised its position in shares of Albemarle by 218.8% in the third quarter. Jennison Associates LLC now owns 4,147,707 shares of the specialty chemicals company’s stock worth $354,587,000 after buying an additional 2,846,734 shares in the last quarter. Institutional investors and hedge funds own 86.50% of the company’s stock.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/19/albemarle-co-alb-receives-consensus-rating-of-buy-from-brokerages.html.

About Albemarle

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

5 Day Chart for NYSE:ALB

Receive News & Ratings for Albemarle Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle Co. and related companies with MarketBeat.com's FREE daily email newsletter.